As part of a community healthcare system, Sutter Cancer Centers actively participate in National Cancer Institute studies searching for ways to prevent cancer. By taking part in prevention research, Sutter supports the future of patients everywhere.

The hundreds of current and past prevention trial volunteers are special people who believe in giving back. Their efforts will ensure that countless men and women will never face a cancer diagnosis.

Since the National Cancer Institute's first cancer prevention study was initiated in 1992, Sutter Cancer Center, Sacramento has been among the nation's carefully selected research sites. The Sacramento center also coordinates participation at Sutter Cancer Center, Roseville and other Sutter Health sites.

Highlights of the center's prevention research history include:

1992	The first National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial began enrolling participants. The study followed more than 13,000 pre- and postmenopausal women to discover if the drug tamoxifen could reduce cancer incidence in women at risk.
1994	Sutter Cancer Center, Sacramento enrolled more than 300 men in its first Prostate Cancer Prevention Trial to determine whether taking the drug finasteride lessened a man's chances of developing prostate cancer.
1996	Sutter Cancer Center, Sacramento received an outstanding achievement award from the National Surgical Adjuvant Breast and Bowel Project (NSABP).
2000	Study of Tamoxifen and Raloxifene (STAR) trial began enrolling participants. The five-year study compares the drugs' effectiveness in preventing breast cancer incidence in women at risk.
2002	Sutter began enrolling men for the SELECT (Selenium and Vitamin E Cancer Prevention Trial) studying whether vitamin E and selenium supplements can reduce the incidence of prostate cancer in men with elevated PSA levels.

If you are interested in participating in a future cancer prevention trial, please call (916) 454-6595.